{
  "nctId": "NCT04865978",
  "briefTitle": "Evaluation of the Hemocompatibility of the Direct Oral Anti-Coagulant Apixaban in Left Ventricular Assist Devices",
  "officialTitle": "Evaluation of the Hemocompatibility of the Direct Oral Anti-Coagulant Apixaban in Left Ventricular Assist Devices",
  "protocolDocument": {
    "nctId": "NCT04865978",
    "filename": "Prot_SAP_000.pdf",
    "label": "Study Protocol and Statistical Analysis Plan",
    "date": "2021-11-08",
    "uploadDate": "2024-10-21T16:26",
    "size": 681410,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT04865978/document/Prot_SAP_000.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": false
  },
  "phase": [
    "PHASE2"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "PARALLEL",
  "masking": "NONE",
  "enrollmentInfo": {
    "enrollmentCount": 30,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2021-12-14",
    "completionDate": "2023-11-07",
    "primaryCompletionDate": "2023-10-05",
    "firstSubmitDate": "2021-04-26",
    "firstPostDate": "2021-04-29"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n1. Patients implanted with a HeartMate 3 LVAD\n2. Age 18 or greater and able to provide written informed consent\n3. Females of childbearing age must agree to adequate contraception\n\nExclusion Criteria:\n\n1. History of post-LVAD device thrombosis, stroke, or gastrointestinal bleeding\n2. Patients who are bridge to transplant and a current UNOS status 1-3\n3. Ongoing inotrope therapy after LVAD (e.g., milrinone, dobutamine, epinephrine)\n4. Permanent right ventricular assist device at the time of LVAD implant\n5. Patients with a mechanical heart valve\n6. Patients with end-stage renal disease on dialysis\n7. Pregnant patients\n8. Known history of ischemic stroke, intracranial bleed, or neurosurgery within 3 months\n9. Known history of intracerebral arteriovenous malformation, cerebral aneurysm or mass lesions of the central nervous system.\n10. Recent (\\<48 hours) or planned spinal or epidural anesthesia or puncture\n11. Prior history of known thrombophilia (e.g., factor V Leiden, prothrombin gene mutation, protein C or S deficiency, antithrombin 3 deficiency, hyperhomocysteinemia, antiphospholipid antibody syndrome) or indication for higher INR goal (\\>2.5) with warfarin.\n12. Thrombolysis within the previous 7 days\n13. Patients with an allergy or contraindication to aspirin, warfarin, or apixaban\n14. Patients on antiplatelet therapy other than aspirin (e.g., clopidogrel, prasugrel, ticagrelor, dipyridamole, or pentoxifylline)\n15. Patients on combined P-glycoprotein and strong CPY3A4 inhibitors or inducers (e.g., fluconazole, posaconazole, rifampin)\n16. Known bleeding within the last 30 days requiring emergency room presentation or hospitalization\n17. Known history of an inherited bleeding disorder (e.g., hemophilia, von Willebrand disease)\n18. Patients with active bleeding or a hemoglobin \\< 8.0 g/dl\n19. Total bilirubin \\> 2.0 mg/dl, shock liver, hepatic encephalopathy, or biopsy proven liver cirrhosis\n20. INR \\> 2.0 not due to anticoagulation therapy\n21. Platelet count \\<100,000 cells/mm3",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": "99 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Freedom From Death or Hemocompatibility Related Adverse Events (Stroke, Device Thrombosis, Bleeding, Aortic Root Thrombus, and Arterial Non-CNS Thromboembolism)",
        "description": "Freedom from death or hemocompatibility related adverse events (composite of stroke, device thrombosis, bleeding, aortic root thrombus, and arterial non-CNS thromboembolism)",
        "timeFrame": "From enrollment to end of treatment at 24 weeks"
      }
    ],
    "secondary": [
      {
        "measure": "Survival Free of Any Stroke",
        "description": "Compared between each study arm",
        "timeFrame": "From enrollment to end of treatment at 24 weeks"
      },
      {
        "measure": "Survival Free of Ischemic Stroke",
        "description": "Compared between each study arm",
        "timeFrame": "From enrollment to end of treatment at 24 weeks"
      },
      {
        "measure": "Survival Free of Hemorrhagic Stroke",
        "description": "Compared between each study arm",
        "timeFrame": "From enrollment to end of treatment at 24 weeks"
      },
      {
        "measure": "Survival Free of Device Thrombosis",
        "description": "Compared between each study arm",
        "timeFrame": "From enrollment to end of treatment at 24 weeks"
      },
      {
        "measure": "Survival Free of Gastrointestinal Bleeding",
        "description": "Compared between each study arm",
        "timeFrame": "From enrollment to end of treatment at 24 weeks"
      },
      {
        "measure": "Survival Free of Major Non-gastrointestinal Bleeding",
        "description": "Compared between each study arm",
        "timeFrame": "From enrollment to end of treatment at 24 weeks"
      },
      {
        "measure": "All-cause Mortality",
        "description": "Compared between each study arm",
        "timeFrame": "From enrollment to end of treatment at 24 weeks"
      },
      {
        "measure": "Cardiovascular Mortality",
        "description": "Compared between each study arm",
        "timeFrame": "From enrollment to end of treatment at 24 weeks"
      },
      {
        "measure": "Survival Free of Aortic Root Thrombus",
        "description": "Compared between each study arm",
        "timeFrame": "From enrollment to end of treatment at 24 weeks"
      }
    ],
    "other": [
      {
        "measure": "Freedom From Death or Hemocompatibility Related Adverse Events Evaluated in Subgroups of Patients Within 3 Months of Implant Versus Greater Than 3 Months From LVAD Implant",
        "description": "Freedom From Death or Hemocompatibility Related Adverse Events (composite of Stroke, Device Thrombosis, Bleeding, Aortic Root Thrombus, and Arterial Non-CNS Thromboembolism) evaluated in subgroups of patients within 3 months of implant versus greater than 3 months from LVAD implant",
        "timeFrame": "From enrollment to end of treatment at 24 weeks"
      }
    ]
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 9,
      "otherCount": 1,
      "totalCount": 11
    },
    "studyDesign": {
      "phases": [
        "PHASE2"
      ],
      "isRandomized": true,
      "isMasked": false,
      "interventionModel": "PARALLEL"
    },
    "overallComplexityScore": 71,
    "complexityCategory": "Complex"
  },
  "collectionDate": "2025-09-22T02:29:31.316Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}